Scara5-flox Mouse
一般名
Scara5-flox
製品ID
S-CKO-17704
背景情報
C57BL/6JCya
系統ID
CKOCMP-71145-Scara5-B6J-VC
状況
このマウス系統を論文で使用する場合は、「Scara5-flox Mouse(カタログ番号S-CKO-17704)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Scara5-flox
系統ID
CKOCMP-71145-Scara5-B6J-VC
遺伝子名
製品ID
S-CKO-17704
遺伝子別名
4932433F15Rik, 4933425F03Rik, Tesr
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 14
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000022610
NCBIトランスクリプトID
NM_028903
ターゲット領域
Exon 2~8
有効領域の大きさ
~94.6 kb
遺伝子研究の概要
Scara5, short for Scavenger receptor class A member 5, has been implicated in multiple biological processes related to cancer and thrombosis-hemostasis. It is believed to play a role in pathways such as epithelial-mesenchymal transition (EMT), and is associated with the clearance of VWF-FVIII complex [2]. It holds significance in understanding the development and progression of various diseases, and genetic models could be valuable in further exploring its functions.
In cancer research, Scara5 shows diverse roles. In gastric cancer, its down-regulation, associated with promoter methylation, is related to aggressive clinicopathological characteristics. Overexpression of Scara5 suppresses the growth, migration, and invasion of gastric cancer cells in vitro and in xenograft models, likely via inhibiting EMT and inactivating MMP-2 and MMP-9 [1]. In bladder cancer, its expression is downregulated, and overexpression reduces cell viability, colony formation, invasion, and migration. It is a downstream factor of the PCAT29/miR-141 axis [3]. In oral squamous cell carcinoma, Scara5 overexpression inhibits cell proliferation, induces apoptosis, and represses EMT, through inactivating the STAT3 and PI3K/AKT signaling pathways [4]. In colorectal cancer, Scara5 in bone marrow stromal cell-derived exosomes inhibits CRC progression by inactivating the PI3K/Akt pathway [5]. In esophageal squamous cell carcinoma, Scara5 suppresses cell cycle, metastasis, and invasion by inducing ferroptosis through combining with ferritin light chain [6]. In nasopharyngeal carcinoma, promoter methylation downregulates Scara5, and its overexpression inhibits cell migration, invasion, and proliferation, and enhances sensitivity to chemotherapy [7]. In melanoma, decreased Scara5 expression is associated with poor prognosis and is related to immune infiltration levels [8]. In colorectal cancer, SCARA5 mRNA levels are downregulated, and low expression is associated with poor prognosis [9].
In conclusion, Scara5 is involved in important biological functions mainly related to cancer development and progression. Through various in vivo and in vitro functional studies, especially in cancer models, it has been shown to play a role as a potential tumor suppressor in multiple cancer types, and may also be related to thrombosis-hemostasis processes. Understanding Scara5 provides insights into disease mechanisms and potential therapeutic targets.
References:
1. Zhang, Hangyu, Liu, Changgang, Wang, Xinbo, Wang, Yongfang, Zheng, Jie. 2021. SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression. In Journal of Cancer, 12, 2412-2421. doi:10.7150/jca.52426. https://pubmed.ncbi.nlm.nih.gov/33758617/
2. Swystun, Laura L, Michels, Alison, Lillicrap, David. 2023. The contribution of the sinusoidal endothelial cell receptors CLEC4M, stabilin-2, and SCARA5 to VWF-FVIII clearance in thrombosis and hemostasis. In Journal of thrombosis and haemostasis : JTH, 21, 2007-2019. doi:10.1016/j.jtha.2023.04.014. https://pubmed.ncbi.nlm.nih.gov/37085036/
3. Lu, Xin-Sheng, Huang, Meng-Long, Chen, Li-Bo, Huang, Zhong-Xin, Liu, Shi-Min. 2023. SCARA5 as a downstream factor of PCAT29, inhibits proliferation, migration, and invasion of bladder cancer. In Genomics, 115, 110667. doi:10.1016/j.ygeno.2023.110667. https://pubmed.ncbi.nlm.nih.gov/37315873/
4. Huang, Juan, Lv, Chunhua, Zhao, Baoyu, Ji, Zhongqian, Gao, Zhenran. 2023. SCARA5 inhibits oral squamous cell carcinoma via inactivating the STAT3 and PI3K/AKT signaling pathways. In Open medicine (Warsaw, Poland), 18, 20230627. doi:10.1515/med-2023-0627. https://pubmed.ncbi.nlm.nih.gov/36785765/
5. Fang, Yu, Wu, Feng, Shang, Guoyin, Yin, Changqing. 2023. SCARA5 in bone marrow stromal cell-derived exosomes inhibits colorectal cancer progression by inactivating the PI3K/Akt pathway. In Genomics, 115, 110636. doi:10.1016/j.ygeno.2023.110636. https://pubmed.ncbi.nlm.nih.gov/37150230/
6. Liu, Yanqun, Xiong, Rong, Xiao, Ting, Song, Guiqin, Liu, Kang. 2022. SCARA5 induced ferroptosis to effect ESCC proliferation and metastasis by combining with Ferritin light chain. In BMC cancer, 22, 1304. doi:10.1186/s12885-022-10414-9. https://pubmed.ncbi.nlm.nih.gov/36513999/
7. Jiang, Xianyao, Jiang, Yu, An, Deqiang, Ji, Ping, Yang, Yucheng. 2023. Methylated tumor suppressor gene SCARA5 inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma. In Epigenomics, 15, 635-650. doi:10.2217/epi-2023-0154. https://pubmed.ncbi.nlm.nih.gov/37554122/
8. Ni, Qinggan, Li, Xia, Huang, Hua, Ge, Zili. 2023. Decreased expression of SCARA5 predicts a poor prognosis in melanoma using bioinformatics analysis. In Frontiers in oncology, 13, 1015358. doi:10.3389/fonc.2023.1015358. https://pubmed.ncbi.nlm.nih.gov/37035142/
9. Liu, J, Zeng, M L, Shi, P C, Zhang, J L, Xie, Y P. . SCARA5 is a Novel Biomarker in Colorectal Cancer by Comprehensive Analysis. In Clinical laboratory, 66, . doi:10.7754/Clin.Lab.2019.191015. https://pubmed.ncbi.nlm.nih.gov/32658413/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
